Publications by authors named "Aimara P Morales"
Article Synopsis
- Fragile X syndrome (FXS) is the most common genetic cause of intellectual disability and autism, characterized by synaptic development issues, with mouse models showing symptoms like anxiety and hyperactivity.
- The drug ANAVEX2-73 (blarcamesine), which acts as a sigma-1 receptor agonist, has shown promise in improving cognitive and behavioral issues associated with FXS in mouse studies by normalizing hyperactivity and anxiety-like behaviors.
- The findings suggest that blarcamesine could be a viable treatment option for FXS and potentially other neurodevelopmental disorders due to its effects on synaptic function and receptor activity.
